Tempus unveils whole-genome sequencing assay xH

USA – Tempus AI, a leader in leveraging artificial intelligence to advance precision medicine, has announced the development of its first whole-genome sequencing (WGS) test, named xH.

This new assay is designed to enhance the detection of genetic alterations in hematological malignancies, aiming to support personalized treatment decisions and improve patient outcomes.

The xH test marks Tempus’ inaugural WGS assay, optimized specifically for myeloid malignancies such as Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS), and Myeloproliferative Neoplasms (MPN).

It has demonstrated a high concordance rate of over 98.9% compared to traditional diagnostic methods.

Although currently available for research use only, the company plans to make the assay clinically available within the next year.

This innovative assay is designed to detect all clinically relevant genetic variations, offering a consolidated, cost-effective alternative to multiple diagnostic tests.

By identifying structural variants (SVs) and copy number alterations (CNAs) recommended by guidelines, xH has the potential to advance precision medicine significantly.

Transforming diagnostics and patient care

Eric Lefkofsky, the founder and CEO of Tempus, emphasized the transformative potential of xH: “xH is our first product leveraging the full genome in our effort to provide meaningful insights into complex diseases. By scaling whole-genome sequencing, we are positioned to transform patient care in hematological oncology and eventually all solid tumors.”

A pilot study involving 135 patients highlighted the xH assay’s high sensitivity in detecting genetic alterations across various myeloid malignancies.

The assay showed over 98.9% accuracy in comparison to traditional molecular diagnostic methods, excelling in identifying structural variants and large copy number alterations.

As a company known for its AI-driven precision medicine solutions, Tempus possesses one of the world’s largest multimodal data libraries.

The addition of xH to its platform expands its capabilities, providing clinicians and researchers with a more comprehensive understanding of patients’ unique genetic profiles.

This not only aids in personalized therapy but also offers biopharma collaborators insights that can drive the discovery of new treatments.

Recent milestones for Tempus AI

Tempus AI continues to make significant strides. In 2024, the company reported a 30% increase in annual revenue, reaching approximately US $693 million, with US $200 million generated in the fourth quarter alone—a 35% year-over-year increase.

Furthermore, Tempus AI has made strategic moves, including acquiring genetics firm Ambry and securing FDA clearance for its Tempus ECG-AF device, which identifies patients at risk of atrial fibrillation.

Additionally, the company has formed a partnership with Avacta Therapeutics to leverage AI for advancements in oncology drug development.